BioLoomics is developing safer, more effective cancer medicines through innovative antibody solutions. Our mission is to leverage directed evolution in human cells to discover programmable antibody degraders of therapeutic targets. Our platform combines synthetic biology, robotics, imaging, and machine learning to perform a function-first search of antibody design space at ultra-high throughput. We are building a highly cross-functional team that will do cutting-edge drug discovery and development. We are a people first company. 

A collaborative and rewarding environment for cutting edge innovation of technology, therapies, and science towards a cohesive goal of making better cancer therapies.

Matching 401k, medical, dental, vision and stock options.